TABLE 3.
Pharmacokinetic parameters for and analysis of tafenoquine following administration of tafenoquine with or without dihydroartemisinin-piperaquine or artemether-lumefantrinea
| Analyte and treatment group or parameter | Geometric mean AUC0–∞ (ng · h/ml) | Geometric mean AUC0–last (ng · h/ml) | Geometric mean Cmax (ng/ml) | Geometric mean t1/2 (h) | Median Tmax (h) (range) |
|---|---|---|---|---|---|
| Tafenoquine | |||||
| TQ + DHA-PQP (n = 24) | 109,333.7 | 93,809.3 | 274.7 | 483.9 | 6.0 (6.0–23.0) |
| TQ (n = 24) | 97,195.5 | 88,283.9 | 199.6 | 375.2 | 12.1 (6.0–72.0) |
| CVb (%) | 23.4 | 21.6 | 20.7 | 16.3 | |
| GMR (90% CI) | 1.12 (1.01, 1.26) | 1.06 (0.96, 1.18) | 1.38 (1.25, 1.52) | 1.29 (1.19, 1.40) | |
| Tafenoquine | |||||
| TQ + AL (n = 22) | 102,328.4 | 91,119.3 | 208.4 | 396.5 | 12.1 (2.0–60.0) |
| TQ (n = 24) | 97,195.5 | 88,283.9 | 199.6 | 375.2 | 12.1 (6.0–72.0) |
| CVb (%) | 26.2 | 24.1 | 19.9 | 15.5 | |
| GMR (90% CI) | 1.05 (0.93, 1.20) | 1.03 (0.92, 1.16) | 1.04 (0.95, 1.15) | 1.06 (0.98, 1.14) |
a
CVb, between-subject variability; GMR, geometric mean ratio.